Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antiepileptics Show Risk Of Suicidality, May Cause Labeling Convulsions

Executive Summary

FDA findings of an increased risk of suicidality in patients given antiepileptic drugs will likely lead to broad class labeling changes, according to a MedWatch alert issued Jan. 31

You may also be interested in...



Singulair Safety Division Of Labor: In Search For Suicide Data, Merck Will Scan Studies While FDA Tackles Post-marketing Reports

Merck and FDA are working on parallel tracks to investigate a possible link between its asthma product Singulair (montelukast) and suicidality

Singulair Safety Division Of Labor: In Search For Suicide Data, Merck Will Scan Studies While FDA Tackles Post-marketing Reports

Merck and FDA are working on parallel tracks to investigate a possible link between its asthma product Singulair (montelukast) and suicidality

Approvals & Regulatory Updates, In Brief

Peramivir gets stockpiled in case of influenza outbreak: BioCryst's I.V. antiviral peramivir is currently undergoing a pre-emergency use authorization review that could mean the I.V. product could be a future option in the event of a severe influenza outbreak, the firm announced May 8. CDC has confirmed sensitivity of the swine flu virus to peramivir; 10 of 13 isolates of the H1N1 virus were tested and all showed susceptibility to peramivir. Based on discussions with the HHS/Biomedical Advanced Research and Development Authority, BioCryst is preparing a portion of its inventory of finished peramivir for addition to the Strategic National Stockpile. The inventory could treat approximately one thousand patients. BioCryst also is in negotiations with the Division of Microbiology and Infectious Diseases and the National Institute of Allergy and Infectious Diseases to conduct a study of peramivir in a pediatric patient population. Clinical development of the product is advancing under a $102.6 million, four-year contract from HHS. Preliminary results of a Phase II study aimed at oseltamivir-resistance with an intramuscular formulation were not statistically significant, but a prior study by Shionogi showed efficacy for the I.V. formulation

Related Content

UsernamePublicRestriction

Register

PS049246

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel